These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 3426872)

  • 41. [Determination of Vibrio antibody titers during anti-cholera vaccination].
    Dirimci OT; Cinar V
    Turk Hij Tecr Biyol Derg (1961); 1973; 33(2-3):118-28. PubMed ID: 4807572
    [No Abstract]   [Full Text] [Related]  

  • 42. Intraduodenal inoculation of adult rabbits for evaluating the immunogenicity of genetically attenuated Vibrio cholerae strains.
    García Imia L; Oliva Hernández R; Cedré Marrero B; Valmaseda Pérez T; García Sánchez H; Talavera Coronel A; Pérez Quiñoy JL; Sierra González G
    Lab Anim Sci; 1998 Oct; 48(5):538-41. PubMed ID: 10090073
    [No Abstract]   [Full Text] [Related]  

  • 43. A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection.
    Yan M; Liu G; Diao B; Qiu H; Zhang L; Liang W; Gao S; Kan B
    Vaccine; 2007 May; 25(20):4046-55. PubMed ID: 17428586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
    Viret JF; Dietrich G; Favre D
    Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody response to the protein antigens of "Salmonella typhi" during typhoid infection and following vaccination with a live oral typhoid vaccine Ty21a.
    Chau PY; Tsang RS
    Dev Biol Stand; 1983; 53():29-31. PubMed ID: 6873471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies.
    Grandjean C; Wade TK; Ropartz D; Ernst L; Wade WF
    Pathog Dis; 2013 Mar; 67(2):136-58. PubMed ID: 23620159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Developmental aspects of organism immunoreactivity in vaccination against cholera (author's transl)].
    Gorkova AV; Kuznĕcov OR; Naumsina MS; Adamov AK
    Cesk Epidemiol Mikrobiol Imunol; 1975 May; 24(3):136-42. PubMed ID: 126811
    [No Abstract]   [Full Text] [Related]  

  • 48. Challenges in mucosal vaccines for the control of infectious diseases.
    Azegami T; Yuki Y; Kiyono H
    Int Immunol; 2014 Sep; 26(9):517-28. PubMed ID: 24914172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impairment of immunogenicity of Salmonella typhi Ty21a due to pre-existing cross-reacting intestinal antibodies.
    Forrest BD
    Adv Exp Med Biol; 1995; 371B():1649-52. PubMed ID: 7502875
    [No Abstract]   [Full Text] [Related]  

  • 50. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.
    Gupta RK; Szu SC; Finkelstein RA; Robbins JB
    Infect Immun; 1992 Aug; 60(8):3201-8. PubMed ID: 1639490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors influencing the stability of live oral attenuated bacterial vaccines.
    Cryz SJ; Pasteris O; Varallyay SJ; Fürer E
    Dev Biol Stand; 1996; 87():277-81. PubMed ID: 8854028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera.
    Bondre VP; Sinha VB; Srivastava BS
    FEMS Immunol Med Microbiol; 1997 Dec; 19(4):323-9. PubMed ID: 9537758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunity in cholera.
    Ghosh AK
    Indian J Pathol Bacteriol; 1974 Apr; 17(2):118-25. PubMed ID: 4455619
    [No Abstract]   [Full Text] [Related]  

  • 55. Construction of a Salmonella typhimurium vaccine strain expressing Vibrio cholera CT-B and LPS-O antigen.
    Chen D; Ma Q
    Chin J Biotechnol; 1997; 13(1):43-50. PubMed ID: 9376506
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Local and systemic immune responses to combined vibrio cholerae CVD103-HgR and salmonella typhi ty21a live oral vaccines after primary immunization and reimmunization.
    Kollaritsch H; Cryz SJ; Lang AB; Herzog C; Que JU; Wiedermann G
    Vaccine; 2000 Jul; 18(26):3031-9. PubMed ID: 10825607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cholera and the immune response.
    Holmgren J; Svennerholm AM
    Prog Allergy; 1983; 33():106-19. PubMed ID: 6338509
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
    Metzger WG; Mansouri E; Kronawitter M; Diescher S; Soerensen M; Hurwitz R; Bumann D; Aebischer T; Von Specht BU; Meyer TF
    Vaccine; 2004 Jun; 22(17-18):2273-7. PubMed ID: 15149786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current developments with cholera vaccines: "Where do we go from here?".
    Finkelstein RA
    Prog Clin Biol Res; 1980; 47():133-42. PubMed ID: 7010372
    [No Abstract]   [Full Text] [Related]  

  • 60. [Effect of Vibrio cholerae toxoid on the levels of antibodies of the IgG, IgA and IgM classes in rabbits].
    Aleksandrowicz J; Kudelski Z
    Med Dosw Mikrobiol; 1986; 38(1):15-22. PubMed ID: 3713366
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.